ClinicalTrials.gg
Not yet recruitingNCT06620393DEX-TBIUpdated Oct 1, 2024

Effects of Dexmedetomidine on Agitation in Critically Ill TBI Patients

A Phase 2/3 interventional study of Dexmedetomidine and Placebo in Traumatic Brain Injury and Agitation,Psychomotor, sponsored by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing dexmedetomidine in Brain Injuries, Traumatic — 5 open to participants now, 5 under way, 2 of them phase 3. Dexmedetomidine · Brain Injuries, Traumatic.

Planned enrollment
6th of 10
72 · median 76
Started
2024
the only one that year
Phase 2/3
Only one
of the 10
Registered
5th of 10
by date
Lead sponsor
1 of 10
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal

Among the 10 studies testing dexmedetomidine in Brain Injuries, Traumatic, this one is the 6th largest by planned enrollment, is the only one that started in 2024, is the only one in phase 2/3, and was the 5th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

5 of the 10 studies testing dexmedetomidine in Brain Injuries, Traumatic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing dexmedetomidine in Brain Injuries, Traumatic, or all of them as a file.
02

Study summary

Agitation is a frequent complication following traumatic braing injury in patients admitted to the intensive care unit. This agitation frequently results in the liberal use of rescue drugs such as antipsychotics, sedatives and opiates, which in turn may delay rehabilitation, liberation from mechanical ventilation and emergence from posttraumatic amnesia. Dexmedetomidine may be a better agent given it's light sedative properties. The main objective is to assess the feasibility of conducting a multicenter randomized controlled trial of dexmedetomidine following TBI in the ICU.

Read the detailed description

Following a traumatic brain injury, agitation is reported in 53-57% of patients in the intensive care unit. As it is associated with accidental removal of catheters, tubes and dressings as well as self-extubation, agitation poses a threat to patient safety. In addition, agitation can be accompanied by aggressive behaviors that pose a threat to clinician safety. This agitation frequently results in the liberal use of rescue drugs such as antipsychotics, sedatives and opiates, which in turn may delay rehabilitation, liberation from mechanical ventilation and emergence from posttraumatic amnesia. Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist used for sedation and also has co-analgesic and withdrawal syndrome alleviating properties. Unlike other sedatives, patients remain easily roused when under dexmedetomidine, facilitating contact and removal from mechanical ventilation. In addition, dexmedetomidine does not induce respiratory depression in critically ill patients. The addition of dexmedetomidine may have the potential to reduce the incidence agitation while reducing the use of agitation rescue drugs such as antipsychotics, the use of physical restraints, as well as the time to cessation of mechanical ventilation and consequently, reduce the time to emergence for post-traumatic amnesia. Duration of posttraumatic amnesia is an important outcome as it is a predictor of cognitive and functional outcomes as well as community integration, psychosocial functioning and employment. The main objective is to assess the feasibility of conducting a multicenter randomized controlled trial of dexmedetomidine following TBI in the ICU. To evaluate the feasibility of conducting a large trial and to refine study procedures, a multicenter randomized double-blind placebo-controlled pilot study comparing dexmedetomidine to placebo will be conducted. The feasibility outcomes will include protocol adherence, trial recruitment and time-in-motion evaluation for study procedures. Clinical outcomes will include agitation, exposure to antipsychotics, time to emergence from post-traumatic amnesia, physical restraint use, ventilator days, and time to ICU and hospital discharge as well as ICU and hospital mortality.

03

Conditions studied

  • Traumatic Brain Injury
  • Agitation,Psychomotor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults (≥18 years) admitted to ICU with a critically ill moderate or severe TBI patients. Severity of TBI will be determined with the first Glasgow Coma Score (GCS). TBI patients with polytrauma and patients undergoing neurosurgical interventions will be eligible.
  2. Undergoing mechanically ventilation (of any duration) at the time of assessment.
  3. Anticipated ICU stay of 48 hours or more.

Exclusion criteria

Exclusion Criteria:

  1. Patients at very high risk of short-term mortality (e.g., GCS of 3 without sedation, or unreactive pupils, or declared brain-dead when assessed for eligibility and patients in whom there is a lack of commitment to ongoing life support
  2. Patients unable to communicate in English or French (interfering with posttraumatic amnesia assessments)
  3. Patients with cognitive impairment as per family evaluation
  4. Pregnant or breastfeeding
  5. Patients currently receiving DEX or clonidine
  6. Allergy, bradycardia or hypotension precluding use of dexmedetomidine as per treating physician
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Dexmedetomidine

    DEX (4 mcg/100 ml supplied by Juno Pharmaceuticals) will be initiated at a starting dose of 0.6 mcg/kg/hour and increased by 0.2 mcg/kg/hour every 30 minutes up to final dose of 1.4 mcg/kg/hour.

    Drug: Dexmedetomidine

  • Placebo comparator
    Placebo

    Matching placebo (NS 0.9% 100ml)

    Drug: Placebo

Interventions

  • DEX 4 mcg/100 ml at a starting dose of 0.6 mcg/kg/hour and increased by 0.2 mcg/kg/hour every 30 minutes up to final dose of 1.4 mcg/kg/hour.

    Also known as: Precedex

  • DrugPlacebo

    NaCl 0.9% 100ml

06

What researchers measure

Primary outcomes

  1. Protocol adherence

    Proportion of hours the drug was administered

    Time frame: Through study completion, an average of 2 years

Secondary outcomes

  1. Trial recruitment

    Recruitment rate and randomization/activation process (consent rate, proportion of recruited patients who receive the study drug)

    Time frame: Through study completion, an average of 2 years

  2. Blinding maintenance

    Proportion of intensivists and nurses predicting study group assignment at the end of the study intervention and proportion of patients receiving propofol

    Time frame: Through study completion, an average of 2 years

  3. Proportion of data collection completed

    Data collection completeness for agitation-related events, posttraumatic amnesia and cognitive recovery

    Time frame: Through study completion, an average of 2 years

Other outcomes

  1. ICU-days free of agitation or coma within 14 days following randomization

    Number of ICU-days without agitation or coma within 14 days following randomization

    Time frame: During ICU stay up to 14 days

  2. Agitation-related event during the ICU stay

    Accidental device removal, self-extubation following randomization in the ICU

    Time frame: Through study completion, an average of 2 years

  3. Proportion of patients and the number of days exposed to antipsychotics, benzodiazepines and physical restraints

    Exposure to antipsychotics, benzodiazepines and physical restraints after randomization during ICU stay

    Time frame: Through study completion, an average of 2 years

  4. Time to mechanical ventilation liberation (extubation), time to ICU and hospital discharge

    Time to mechanical ventilation liberation (extubation), time to ICU and hospital discharge

    Time frame: Through study completion, an average of 2 years

  5. Time to emergence from posttraumatic amnesia

    Time from randomisation to emergence from posttraumatic amnesia

    Time frame: Through study completion, an average of 2 years

  6. Cognitive recovery

    Brief cognitive assessment in traumatology (EXACT) score (0-100 points); higher scores reflect better function

    Time frame: Through study completion, an average of 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2024; primary completion for Jun 2026, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2024
First posted
Oct 1, 2024
StartEst.
Oct 1, 2024
Primary completionEst.
Jun 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06620393
Lead sponsor
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Collaborators
Canadian Critical Care Trials Group
Responsible party
David Williamson (Full Clinical Professor, Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal) — Principal investigator
First posted
Oct 1, 2024
Start date
Oct 1, 2024 (estimated)
Primary completion
Jun 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Oct 1, 2024

Study contacts

Virginie Williams, PhD
Contact
virginie.williams.cnmtl@ssss.gouv.qc.ca
514-338-2222

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion